Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,270
Recruiting: 2,320
Ph III recruiting: 270
Growth YoY: +13.6%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 2,151–2,200 of 2,315 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06508229	Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC	not yet recruiting	Phase 2	65	Harbin Medical UniversityOTHER	0	Jul 18, 2024	clinicaltrials
NCT06354140	PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY	recruiting	Phase 2	45	Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER